Stoke Therapeutics to Present at Upcoming Investor Conferences in March
TD Cowen 45th Annual Healthcare Conference
Date: Wednesday, March 5, 2025
Time: 9:50 a.m. ET
Leerink Partners Global Healthcare Conference
Date: Monday, March 10, 2025
Time: 10:40 a.m. ET
Live webcasts of each event, along with archived replays, will be available in the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is expected to enter Phase 3 development in 2025. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226132780/en/
Stoke Media & Investor Contacts:
Dawn Kalmar
Chief Communications Officer
dkalmar@stoketherapeutics.com
781-303-8302
Doug Snow
Director, Communications & Investor Relations
IR@stoketherapeutics.com
508-642-6485
Source: Stoke Therapeutics, Inc.